ABSTRACT Alzheimer's disease (AD) is a complex neurodegenerative disorder affecting millions of Americans, yet therapeutic options to prevent, slow, or cure AD and related dementias (ADRD) remain limited. The multifactorial nature of AD/ADRD along with a heterogeneous presentation across individuals, necessitates multiple therapeutic approaches. The National Institute on Aging (NIA) has established a series of research programs to diversify the therapeutic pipeline, including the Accelerating Medicines Partnership in Alzheimer's Disease Target Discovery and Preclinical Validation project (AMP-AD) and dozens of additional consortia and projects. These programs employ open science practices to understand the molecular complexity of AD/ADRD and identify new avenues for treatment. The Data Coordination Center (DCC), led by Sage Bionetworks, supports these programs by overseeing dissemination of research outputs through the AD Knowledge Portal and the Agora Platform. These platforms have been widely utilized, with thousands of researchers having accessed data and hundreds of publications referencing their use. The DCC also promotes cross-project integrative analyses through working groups, which have yielded significant contributions in terms of harmonized datasets and cross-consortium publications. As the AD Knowledge Portal Data Coordination Center, we will leverage and expand our existing processes, systems, and infrastructure to further our mission to accelerate translational research in AD. We propose to: 1) apply Findable, Accessible, Interoperable, Reusable (FAIR) practices to define data and metadata standards and oversee data contribution and governance; 2) use evidence-based strategies to engage the consortium in collaborative cross-team research projects; (3) disseminate consortium-generated resources through the AD Knowledge Portal and Agora and develop interoperability with the broader ecosystem of AD/ADRD data and resources; and 4) maximize the impact of AD Knowledge Portal resources on basic and translational AD/ADRD research through outreach and engagement with the broader research community.